^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GB222 (bevacizumab biosimilar)

    i
    Other names: GB222
    Associations

    News

    Trials
    Company:
    Walvax
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed. (ASCO 2023)
    Clinical benefit was observed across most patient subgroups, with a trend of higher ORR in pts with squamous cell carcinoma, no previous bevacizumab use and higher CPS. GB226 demonstrated durable antitumor activity and manageable safety profile in pts with recurrent or metastatic cervical cancer. Clinical trial information: NCT03808857.
    Clinical • P2 data • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Aibining (geptanolimab) • GB222 (bevacizumab biosimilar)
    almost4years
    Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    No abstract available
    Clinical • New P2 trial
    |
    ALB (Albumin)
    |
    Avastin (bevacizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Onivyde (nanoliposomal irinotecan) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    almost4years
    Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    Clinical • New P2 trial
    |
    ALB (Albumin)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)